Coumadin

(Warfarin)

ApprovedSmall molecule

Warfarin is a blood thinner used to prevent blood clots that could cause strokes, heart attacks, or other serious conditions. It's commonly prescribed to patients with irregular heartbeat, those who have had blood clots, or people with certain heart valve replacements.[2] Coumadin is currently approved and in use across 48 indications[4].[1]

Coumadin is one of 781 small molecule programs targeting Thrombophlebitis. It is currently in Approved.

Indications

316

Total Trials

Active Trials

780

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

ThrombophlebitisApproved

CalcificationActive, not recruiting

Cirrhosis of LiverApproved

Cardiovascular DiseaseApproved

MetastasisApproved

Atrial FlutterApproved

Heart Valve DiseaseApproved

Essential HypertensionApproved

Venous ThromboembolismCompleted

Thrombotic DiseaseActive, not recruiting

ThrombophlebitisApproved

Approved

CalcificationApproved

Active, not recruiting

Cirrhosis of LiverApproved

Approved

Cardiovascular DiseaseApproved

Approved

MetastasisApproved

Approved

Atrial FlutterApproved

Approved

Heart Valve DiseaseApproved

Approved

Essential HypertensionApproved

Approved

Venous ThromboembolismApproved

Completed

Thrombotic DiseaseApproved

Active, not recruiting

Showing 10 of 46 indications

Competition

Competitive Landscape

198 competitors in Heart Failure

#DrugCompanyPhaseTrials

Coumadin

AAbbott

Approved

1 2

Bayer Aspirin

Bayer

Preclinical

2 3

Medrol

Pfizer

Preclinical

1 4

Amidate

Pfizer

Preclinical

1 5

Activase

Zemplar

Adriamycin

Savaysa

Xifaxan

2 10

Xylocaine

MMEDRx USA, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalRecruiting

Atrial Fibrillation

NCT03862859

Q2 2027

Post-ApprovalRecruiting

Heart Failure

NCT06655376

Q3 2027

Post-ApprovalActive, not recruiting

Atrial Fibrillation

NCT04045093

Q4 2027

Post-ApprovalRecruiting

Mitral Valve Repair

NCT06738992

Clinical

Trials by Indication[1]

Atrial Fibrillation42 trials

The Effect and Safety of Different Intensity Anticoagulation Therapy in Elderly Patients With Non-valvular Atrial Fibrillation

Completed·NNanjing Medical University·Phase 4·NCT01438580·260 enrolled

A Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation

Unknown status·TThe Second Affiliated Hospital of Chongqing Medical University·N/A·NCT03792152·80 enrolled

WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation

Completed·BBoston Scientific Corporation·Phase 2/3·NCT00129545·800 enrolled

Show 39 more trials

Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data

Completed· Pfizer logo

Pfizer··NCT05438888·77,814 enrolled

A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01136408·174 enrolled

Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively

Terminated·HHospital Ana Nery·Phase 2/3·NCT01868243·27 enrolled

A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin

Completed· Bayer logo

Bayer··NCT05022758·45,000 enrolled

Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02769078·14,201 enrolled

Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Completed· Astellas logo

Astellas·Phase 2·NCT00448214·448 enrolled

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00580216·3,773 enrolled

A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation

Completed· Astellas logo

Astellas·Phase 2·NCT00938730·1,280 enrolled

ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)

Completed·UUniversity of Pavia·Phase 4·NCT02935855·300 enrolled

Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis

Completed·UUnity Health Toronto·Phase 2·NCT03987711·151 enrolled

Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation

Terminated·MMayo Clinic·Phase 3·NCT03839355·34 enrolled

Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy

Completed·BBoston Scientific Corporation·Phase 3·NCT01182441·407 enrolled

Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)

Completed· Bayer logo

Bayer··NCT04249401·134,897 enrolled

Direct Oral Anticoagulants in Patients with Atrial Fibrillation (DOACs Vs Warfarin)

Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT03596502·402,764 enrolled

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00403767·14,269 enrolled

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00412984·20,976 enrolled

Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation

Completed·—·Phase 2·NCT02042534·195 enrolled

Dabigatran for Mitral Stenosis Atrial Fibrillation

Active, not recruiting·TThe University of Hong Kong·Phase 4·NCT04045093·370 enrolled

Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT02072434·2,199 enrolled

Hirudin Plus Aspirin in the Secondary Prevention of Cardioembolic Stroke Due to Nonvalvular Atrial Fibrillation

Completed·XXijing Hospital··NCT02181361·239 enrolled

Left Atrial Appendage (LAA) Occluders After Catheter Ablation of Atrial Fibrillation

Completed·MMeshalkin Research Institute of Pathology of Circulation·Phase 2·NCT01695824·96 enrolled

Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease

Completed·—·Phase 4·NCT02982850·120 enrolled

Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants

Completed·UUniversity of Sao Paulo General Hospital·Phase 3·NCT03181386·60 enrolled

Dabigatran in Patients With Atrial Fibrillation and Mitral Biological Prostheses

Unknown status·RResearch Institute for Complex Problems of Cardiovascular Diseases, Russia·Phase 4·NCT03183843·40 enrolled

The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis

Recruiting·NNicholas Carlson·Phase 4·NCT03862859·718 enrolled

RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial

Completed·HHospital do Coracao·Phase 2·NCT02303795·1,005 enrolled

Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice

Completed· Bayer logo

Bayer··NCT03847181·45,164 enrolled

A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT03189069·36,000 enrolled

A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT00504556·1,146 enrolled

Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02754154·321,182 enrolled

BAY59-7939 in Atrial Fibrillation Once Daily (OD)

Completed· Bayer logo

Bayer·Phase 2·NCT00973245·102 enrolled

Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis

Recruiting·SSung-Hwan Kim·Phase 2·NCT05540587·240 enrolled

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation

Completed·IIntermountain Health Care, Inc.·Phase 4·NCT03061006·101 enrolled

Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation

Completed· Pfizer logo

Pfizer··NCT05321810·193,565 enrolled

EdoxabaN or Warfarin Therapy In Device Procedures in Patients With Non-Valvular Atrial Fibrillation

Terminated·EElectrophysiology Research Foundation·Phase 4·NCT02561897·5 enrolled

Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy

Completed·—·Phase 4·NCT03463317·912 enrolled

A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes

Completed· Bayer logo

Bayer··NCT04509193·116,049 enrolled

Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty

Unknown status·—··NCT04878497·1,000,000 enrolled

Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)

Completed·MMassachusetts General Hospital·Phase 3·NCT00000517

Interaction9 trials

Drug-Drug Interaction Study to Assess the Effects of Steady State Pitavastatin 4 mg or Rosuvastatin 40 mg on Steady-State Warfarin in Healthy Adult Volunteers

Completed·KKowa Research Institute, Inc.·Phase 4·NCT01178853·48 enrolled

A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin

Completed·HHangzhou Sciwind Biosciences Co., Ltd.·Phase 1·NCT06335134·57 enrolled

Drug-drug Interaction Study(Lobeglitazone, Warfarin)

Completed· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 1·NCT02002611·24 enrolled

Show 6 more trials

Pharmacokinetic Drug-Drug Interaction Study of Rucaparib

Completed·Ppharmaand GmbH·Phase 1·NCT02740712·17 enrolled

Interaction Between ABT-335, Rosuvastatin and Warfarin

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00487136·45 enrolled

Drug-Drug Interaction Study to Assess the Effects of Multiple-Dose Administration of K-877 on the Pharmacodynamics and the Pharmacokinetics of Multiple-Dose Administration of Warfarin in Healthy Adult Volunteers

Completed·KKowa Research Institute, Inc.·Phase 1·NCT02719431·20 enrolled

Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study

Completed·KKnopp Biosciences·Phase 1·NCT01597310·15 enrolled

A Drug-Drug Interaction Study of Warfarin and PA21

Completed·VVifor Pharma·Phase 1·NCT01477424·45 enrolled

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

Completed·MMirati Therapeutics Inc.·Phase 1·NCT04887194·40 enrolled

Anticoagulant9 trials

Replication of the ROCKET-AF Anticoagulant Trial in Healthcare Claims Data

Completed·—··NCT04593056·102,636 enrolled

Replication of the RELY Anticoagulant Trial in Healthcare Claims Data

Completed·—··NCT04593043·78,140 enrolled

Anticoagulant After Implantation of Biological Aortic Valve Comparing With Aspirin

Completed·RRigshospitalet, Denmark·Phase 4·NCT01452568·370 enrolled

Show 6 more trials

Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data

Completed·—··NCT04593030·220,518 enrolled

Pleotropic Effect of New Oral Anticoagulants

Unknown status·KKyunghee University Medical Center·Phase 3·NCT02544932·55 enrolled

Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data

Completed·—··NCT04879407·98,947 enrolled

Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants

Completed·AAzienda Ospedaliera Universitaria Policlinico·Phase 4·NCT00438230·250 enrolled

Start or STop Anticoagulants Randomised Trial (SoSTART)

Completed·UUniversity of Edinburgh·Phase 3·NCT03153150·203 enrolled

Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data

Completed·—··NCT04736719·19,002 enrolled

Venous Thromboembolism8 trials

Treatment Patterns Among Patients With Venous Thromboembolism in the United States

Completed· Pfizer logo

Pfizer··NCT05795062·13,945 enrolled

Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer

Completed· LEO Pharma logo

LEO Pharma·Phase 3·NCT01130025·900 enrolled

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Completed· Bayer logo

Bayer·Phase 3·NCT01516840·60 enrolled

Show 5 more trials

Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data

Completed·JJohns Hopkins University··NCT04818151·14,914 enrolled

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00680186·2,589 enrolled

An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism

Completed· Bayer logo

Bayer··NCT06278051·320 enrolled

Odiparcil For The Prevention Of Venous Thromboembolism

Completed· GSK logo

GSK·Phase 2·NCT00244725·961 enrolled

Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients

Completed· Bayer logo

Bayer·Phase 3·NCT01516814·40 enrolled

Venous thrombosis6 trials

COMPARISON OF WARFARIN AND RIVAROXABAN IN THE TREATMENT OF LOWER LIMB DEEP VENOUS THROMBOSIS

Completed·—·Phase 1·NCT07077954·74 enrolled

Comparison Between Xarelto Versus Warfarin in the Recanalization Rate of Deep Venous Thrombosis in Patients Legs.

Unknown status·—·N/A·NCT02704598·84 enrolled

Prevention of Venous Thrombosis After Permanent Transvenous Leads Implantation

Completed·UUniversity of Sao Paulo·N/A·NCT00621491·101 enrolled

Show 3 more trials

Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)··NCT00005684

Prevention of Recurrence After Thrombolysis in Acute Iliofemoral Venous Thrombosis (PRAIS) Study

Unknown status·SSeoul National University Hospital·N/A·NCT01986192·72 enrolled

The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis

Unknown status·—·Phase 3·NCT03217448·80 enrolled

73 more indications

Rivaroxaban6 trials

Efficacy Comparison of Warfarin Versus Rivaroxaban CVT

Unknown status·IIsfahan University of Medical Sciences·Phase 1/2·NCT03747081·50 enrolled

Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis

Terminated·HHospital Geral Roberto Santos·Phase 2/3·NCT03566303·50 enrolled

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Completed· Bayer logo

Bayer··NCT01947998·50,299 enrolled

Show 3 more trials

Rivaroxaban vs. Warfarin in CVT Treatment

Completed·—·Phase 3·NCT04569279·71 enrolled

Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves

Enrolling by invitation·—·Phase 3·NCT07456085·60 enrolled

Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium

Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 4·NCT02376010·110 enrolled

Pulmonary Embolism5 trials

Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial. "PADIS-PE" Study.

Completed·UUniversity Hospital, Brest·Phase 3·NCT00740883·374 enrolled

XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis

Terminated·SSusan Smyth·Phase 4·NCT02506985·10 enrolled

Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach

Completed· Sanofi logo

Sanofi·Phase 3·NCT00345618·3,202 enrolled

Show 2 more trials

STOPping Anticoagulation for Isolated or Incidental Subsegmental Pulmonary Embolism

Unknown status·UUniversity of Birmingham·Phase 3·NCT04727437·1,466 enrolled

Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy

Unknown status·MMeshalkin Research Institute of Pathology of Circulation·Phase 4·NCT02979561·200 enrolled

Trial5 trials

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00235248·350 enrolled

Arterial Disease Multifactorial Intervention Trial (ADMIT)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000539

Personalized Medicine Interface Tool (PerMIT): Warfarin: A Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy

Completed·RRobert Pendleton·Phase 4·NCT00993200·26 enrolled

Show 2 more trials

PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

Terminated·AArtivion Inc.·Phase 3·NCT04142658·863 enrolled

The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)

Active, not recruiting·RRigshospitalet, Denmark·N/A·NCT06449469·352 enrolled

Anticoagulation5 trials

Anticoagulation Regiments in Patients With Prosthetic Heart Valve Thrombosis

Unknown status·KKartal Kosuyolu Yuksek Ihtisas Education and Research Hospital·N/A·NCT02240953·180 enrolled

D-Dimer Determined Anticoagulation INTENSITY in Patients With Mechanical Valve Replacement

Completed·WWuhan Asia Heart Hospital··NCT01996657·772 enrolled

Prospective Evaluation of an Extended Interval of INR Follow-up in a VA Anticoagulation Service

Completed·—·N/A·NCT02392104·51 enrolled

Show 2 more trials

Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT04066764·200 enrolled

Anticoagulation Regimens in Pregnant Patients With Prosthetic Heart Valves

Unknown status·KKartal Kosuyolu Yuksek Ihtisas Education and Research Hospital·N/A·NCT02240927·40 enrolled

Deep Vein Thrombosis5 trials

Prolonged Anticoagulation After a First Episod of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP)

Completed·UUniversity Hospital, Brest·Phase 3·NCT00740493·104 enrolled

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00643201·5,614 enrolled

AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients

Completed· Pfizer logo

Pfizer·Phase 3·NCT01780987·80 enrolled

Show 2 more trials

The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis

Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT00216866·70 enrolled

Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT04067505·224 enrolled

Efficacy and Safety4 trials

Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial)

Completed·YYonsei University·Phase 3·NCT03244319·220 enrolled

Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist Warfarin

Withdrawn·PPharmEvo Pvt Ltd·Phase 4·NCT03673605

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT01662908·85 enrolled

Show 1 more trial

A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02913326·120 enrolled

Midazolam4 trials

Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin

Withdrawn· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02345304

A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Midazolam and Warfarin in Healthy Male Subjects

Completed· Idorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.·Phase 1·NCT05480488·18 enrolled

The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02254148·24 enrolled

Show 1 more trial

A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02617810·18 enrolled

Stroke3 trials

Aspirin Or Warfarin To Prevent Stroke

Terminated·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 3·NCT00004728

PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01227629·502 enrolled

Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation

Completed·UUniversity of South Florida·Phase 3·NCT02283294·91 enrolled

Knee Replacement Surgery2 trials

BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2/3·NCT00097357·1,238 enrolled

Prophylaxis Against DVTs After Primary Hip and Knee Replacement Surgery

Unknown status·TThe New England Baptist Hospital·N/A·NCT00767559·330 enrolled

Coronary Artery Bypass2 trials

Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy

Recruiting·CChina National Center for Cardiovascular Diseases·Phase 4·NCT05782270·202 enrolled

Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery

Unknown status·UUniversity of Sao Paulo General Hospital·Phase 4·NCT05300555·50 enrolled

Atopic Dermatitis2 trials

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

Completed· Amgen logo

Amgen·Phase 1·NCT05891119·21 enrolled

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

Completed· LEO Pharma logo

LEO Pharma·Phase 1·NCT03556592·40 enrolled

Prostate Cancer2 trials

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00004054·397 enrolled

Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00014352

Pulmonary Hypertension2 trials

Use of Ventavis in Patients With Postembolic Residual Pulmonary Hypertension

Unknown status·MMeshalkin Research Institute of Pathology of Circulation·Phase 2·NCT02238535·60 enrolled

Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT01036802·3 enrolled

Calcification2 trials

Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation

Completed·UUniversity Hospital, Angers·Phase 4·NCT02161965·51 enrolled

Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque

Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 4·NCT02090075·66 enrolled

Tics2 trials

Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics

Completed·BBial - Portela C S.A.·Phase 1·NCT04994119·26 enrolled

A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects

Completed· Astellas logo

Astellas·Phase 1·NCT00856570·24 enrolled

Antiphospholipid Syndrome2 trials

Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome

Completed·—·Phase 4·NCT02295475·48 enrolled

RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome

Unknown status·UUniversity College, London·Phase 2·NCT03684564·43 enrolled

Portal vein thrombosis2 trials

Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）

Completed·NNorthern Jiangsu People's Hospital·Phase 4·NCT04645550·120 enrolled

Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy

Unknown status·YYangzhou University·Phase 4·NCT02238444·60 enrolled

Left Ventricular Thrombus2 trials

Apixaban in Patients With Left Ventricular Thrombus

Completed·SSaud Al Babtain Cardiac Center·Phase 3·NCT05208398·50 enrolled

Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI

Completed·RRajaie Cardiovascular Medical and Research Center·Phase 3·NCT05705089·50 enrolled

Prospective2 trials

MAGENTUM 1 HeartMate 3 LVAS: A Single Center Prospective Controlled Study (MAGENTUM 1)

Unknown status·IInstitute for Clinical and Experimental Medicine·N/A·NCT03078374·15 enrolled

Evaluation of Maintenance Dosing vs Loading Dosing Upon Restarting Warfarin Therapy: A Prospective Randomized Trial

Completed·UUniversity of Alberta·Phase 1·NCT01124058·39 enrolled

Effectiveness2 trials

Comparative Effectiveness and Safety Between Warfarin and Dabigatran

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03254134·22,490 enrolled

The Safety and Effectiveness of Warfarin Vs Apixaban in Patients with NVAF/ VTE and ESKD on Dialysis

Completed·AAbu Dhabi Health Services Company··NCT06606275·67 enrolled

After Cardiac Surgery2 trials

The Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery

Active, not recruiting·SSt. Paul's Hospital, Canada·Phase 2·NCT05006287·100 enrolled

DOAC Versus VKA After Cardiac Surgery

Withdrawn·LLaval University·Phase 2·NCT04002011

Complication2 trials

Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.

Active, not recruiting·PPetrovsky National Research Centre of Surgery··NCT07358416·500 enrolled

NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications

Completed·MMalmö University··NCT04662515·216 enrolled

Treatment2 trials

Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01561937·127 enrolled

Treatment for Blood Clots in the Veins of the Legs

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00001713·20 enrolled

Semaglutide2 trials

Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02022254·24 enrolled

A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02070510·52 enrolled

Dapagliflozin1 trial

Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00904176·30 enrolled

Adult1 trial

A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06772779·36 enrolled

Concentration1 trial

Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01311622·15 enrolled

ART1 trial

Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02161731·24 enrolled

Overweight or Obese1 trial

A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT05815680·48 enrolled

Mitral Valve Repair1 trial

Safety and Effectiveness of Early Aspirin Administration After Mitral Valve Repair

Recruiting·GGuangdong Provincial People's Hospital·Phase 4·NCT06738992·384 enrolled

Empagliflozin1 trial

Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01111331·18 enrolled

Telitacicept1 trial

Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE

Unknown status·QQilu Hospital of Shandong University··NCT05644210·80 enrolled

Oligohydramnios1 trial

Warfarine in Unexplained Oligohydramnios

Terminated·WWoman's Health University Hospital, Egypt·Phase 4·NCT01569035·200 enrolled

ARDS1 trial

Assessment of 2012 Bioequivalence Standards for Warfarin

Completed·UUniversity of California, San Francisco·Phase 1·NCT02574754·10 enrolled

Catheter1 trial

Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters

Completed·CCancer Research Campaign Clinical Trials Centre·N/A·NCT00024297

Patent foramen ovale1 trial

Patent Foramen Ovale in Cryptogenic Stroke Study

Completed·—·Phase 4·NCT00697151·630 enrolled

Monotherapy1 trial

Anti-thrombotic Monotherapy in HeartMate 3 Left Ventricular Assist System (LVAS)

Unknown status·IInstitute for Clinical and Experimental Medicine·N/A·NCT03781258·20 enrolled

Adult Subject1 trial

Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects

Completed· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT02461914·16 enrolled

Osteoporosis1 trial

The Effectiveness and Safety of Apixaban in NVAF Patients With History of Osteoporosis and/or Fracture: A Nation-wide Population Based Study

Withdrawn· Pfizer logo

Pfizer··NCT04198844

GastroIntestinal Bleeding1 trial

Compare VKA vs LMWH in Patients With Anticoagulation Criteria and Episode of Gastrointestinal Bleeding.

Completed·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·Phase 4·NCT01727453·40 enrolled

Gene Polymorphism1 trial

The Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR

Unknown status·NNational Taiwan University Hospital·N/A·NCT00247702·120 enrolled

Ablation1 trial

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT02348723·678 enrolled

Prevention1 trial

Secondary Prevention of Venous Thrombo Embolism (VTE).

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00329238·2,867 enrolled

Cardiac1 trial

Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial

Completed·—·Phase 3·NCT00041938·2,305 enrolled

Anticoagulant Therapy1 trial

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00262600·18,113 enrolled

Randomized1 trial

A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT00827034·14 enrolled

Metachromatic Leukodystrophy1 trial

Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy

Completed·TThe Cooper Health System·N/A·NCT00683189·10 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial

Unknown status·PPeshawar Institute of Cardiology·Phase 4·NCT05973188·141 enrolled

Idiopathic Pulmonary Fibrosis1 trial

AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis

Terminated·—·Phase 3·NCT00957242·145 enrolled

TIA1 trial

Validation of Predictors of OAC Initiation Using EMR Data

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03006341·140,187 enrolled

Post-Operative Atrial Fibrillation1 trial

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

Completed·SSanford Health·Phase 2/3·NCT02889562·56 enrolled

Oral1 trial

Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices

Completed·PPalak Shah·Phase 2·NCT04865978·30 enrolled

Hemorrhage1 trial

Hemorrhage Following Small Polyp Resection in the Colon in Anticoagulated Patients

Unknown status·HHadassah Medical Organization·N/A·NCT02375646·286 enrolled

Left Atrial Appendage Closure1 trial

Left Atrial Appendage Closure Compared to Standard Antiplatelet Therapy in Patients With AF Who Underwent PCI

Unknown status·MMeshalkin Research Institute of Pathology of Circulation·Phase 2·NCT02492230·50 enrolled

Heart Failure1 trial

Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device

Recruiting·—·Phase 4·NCT06655376·128 enrolled

Psoriasis1 trial

Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02397382·16 enrolled

AML1 trial

An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates

Active, not recruiting· Sanofi logo

Sanofi·Phase 1·NCT06686628·23 enrolled

Pilot Study1 trial

Apixaban in Patients Who Undergo CIED Procedure- Randomized Pilot Study

Withdrawn·MMayo Clinic·Phase 2·NCT02450682

Pregnant Women1 trial

Use of Warfarin After the First Trimester in Pregnant Women With APS

Unknown status·MMohamed Sayed Abdelhafez·Phase 4·NCT02303171·100 enrolled

Cognitive impairment1 trial

Cognitive Impairment Related to Atrial Fibrillation Prevention Trial

Completed·UUniversity of Sao Paulo·Phase 4·NCT01994265·200 enrolled

Atorvastatin1 trial

A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06289504·34 enrolled

Uterine Bleeding1 trial

A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT04394234·961,985 enrolled

Length of Stay1 trial

Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02631057·4,313 enrolled

Cognition1 trial

AntiCoagulants and COGnition

Unknown status·UUniversity Hospital, Angers·Phase 4·NCT04073316·48 enrolled

Metabolism1 trial

Determinants of Warfarin Metabolism

Unknown status·HHadassah Medical Organization·N/A·NCT00162474·600 enrolled

Thrombosis1 trial

Treatment of Upper Extremity Deep-Vein Thrombosis

Completed·UUniversity of Oklahoma·Phase 4·NCT00245856·67 enrolled

Acute Myocardial Infarction1 trial

Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction

Recruiting·KKarolinska Institutet·Phase 4·NCT06515730·212 enrolled

Direct Oral Anticoagulants (DOACs)1 trial

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

Completed·AAlliance Foundation Trials, LLC.·N/A·NCT02744092·811 enrolled

AIN1 trial

The Study of Warfarin Maintenance Dose in Chinese Patients

Unknown status·—··NCT01855737·1,000 enrolled

Factor Xa Inhibitor1 trial

Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin

Completed·PPortola Pharmaceuticals·Phase 2·NCT00742859·508 enrolled

Hepatitis C Virus Infection1 trial

Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection

Completed·IImperial College London·Phase 2·NCT00180674·14 enrolled

Elderly Patients1 trial

Validation of International Warfarin Pharmacogenetics Consortium (IWPC) Algorithm in Elderly Patients With Comorbidity

Unknown status·UUniversity of Campania Luigi Vanvitelli··NCT02069132·376 enrolled

Unspecified9 trials

Medical Need of OAC Reversal

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03254147·53,969 enrolled

Dabigatran Versus Warfarin With NVAF Who Undergo PCI

Unknown status·SShenyang Northern Hospital·Phase 4·NCT03536611·1,120 enrolled

A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects

Completed· Astellas logo

Astellas·Phase 1·NCT02252731·22 enrolled

Show 6 more trials

Duloxetine - Warfarin Pharmacodynamic Study

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT00533026·60 enrolled

A Study of LY2216684 and Warfarin in Healthy Subjects

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01263119·18 enrolled

Pemvidutide (ALT-801) DDI Study in Healthy Volunteers

Completed· Altimmune logo

Altimmune·Phase 1·NCT04972396·40 enrolled

Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus

Completed·HHadassah Medical Organization·Phase 3·NCT03232398·40 enrolled

Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information

Completed·—·N/A·NCT00401414·344 enrolled

RIvoraxaban in Mitral Stenosis

Terminated·RRajaie Cardiovascular Medical and Research Center·Phase 3·NCT03926156·40 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

ATHROMBIN

NDA NDA011771

Jan 1, 1982

PANWARFIN

NDA NDA017020

Feb 7, 1995

COUMADIN

NDA NDA009218

Sources

References

[1]
ClinicalTrials.gov — 316 trial records for Warfarin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Coumadin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Warfarin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Warfarin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA009218). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Abbott company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Vitamin K Epoxide Reductase Complex Subunit 1 Isoform 1 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AAbbott